Comparative Study of Metaplastic Breast Carcinoma and Triple-Negative Breast Carcinoma Using Histologic and Immunohistochemical Analyses

다국어 초록 (Multilingual Abstract)

Background : Metaplastic carcinoma of the breast is a rare subtype of breast cancer, which is characterized by estrogen receptor/progesterone receptor and HER2 negativity. Methods : Tissue specimens from 60 metaplastic breast cancer and 60 triple-negative breast cancer patients diagnosed at a single institution between 1995 and 2009 were analyzed. Immunohistochemistry for caveolin-1 (CAV-1), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), c-kit, p53, Ki-67, breast cancer type 1 susceptibility protein (BRCA1), cytokeratin (CK)14, and CK17 were performed on both retained tissue sets. Results : Of the 60 metaplastic carcinomas, 15 tumors (25%) exhibited spindle cell component, 27 (45%) exhibited chondroid differentiation, and 18 (30%) exhibited squamous areas. Compared to triple-negative carcinomas, metaplastic carcinomas significantly more frequently expressed CK14 (p < 0.0001), CK17 (p = 0.002), EGFR (p < 0.0001), CAV-1 (p < 0.0001), and VEGF (p = 0.029). However, expressions of BRCA1, p53, c-kit, and Ki-67 were not significantly different between both groups. Conclusions : The expression profile of metaplastic carcinoma of the breast is more homogeneous than that of other triple-negative tumors and frequently over-expresses basal markers, CAV-1, and VEGF. A typical “asal-like”phenotype and frequent expressions of CAV-1 and VEGF may justify specific therapeutic approaches.

참고문헌 (Reference)

1 Jung SY, "Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer" 120 : 627-637, 2010

2 Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2" 344 : 783-792, 2001

3 Rakha EA, "Triple-negative/basal-like breast cancer:review" 41 : 40-47, 2009

4 McKeage K, "Trastuzumab:a review of its use in the treatment of metastatic breast cancer overexpressing HER2" 62 : 209-243, 2002

5 Rosen PP, "Rosen’s breast pathology" Lippincott Williams & Wilkins, a Wolters Kluwer business 470-505, 2009

6 Sorlie T, "Repeated observation of breast tumor subtypes in independent gene expression data sets" 100 : 8418-8423, 2003

7 Weigelt B, "Refinement of breast cancer classification by molecular characterization of histological special types" 216 : 141-150, 2008

8 Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis" 11 : 155-168, 1998

9 Boccadoro M, "Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy" 5 : 18-, 2005

10 Wargotz ES, "Metaplastic carcinomas of the breast:V.metaplastic carcinoma with osteoclastic giant cells" 21 : 1142-1150, 1990

11 Wargotz ES, "Metaplastic carcinomas of the breast:IV.squamous cell carcinoma of ductal origin" 65 : 272-276, 1990

12 Wargotz ES, "Metaplastic carcinomas of the breast:III.carcinosarcoma" 64 : 1490-1499, 1989

13 Wargotz ES, "Metaplastic carcinomas of the breast:II.spindle cell carcinoma" 20 : 732-740, 1989

14 Wargotz ES, "Metaplastic carcinomas of the breast:I.matrixproducing carcinoma" 20 : 628-635, 1989

15 Oberman HA, "Metaplastic carcinoma of the breast:a clinicopathologic study of 29 patients" 11 : 918-929, 1987

16 Leibl S, "Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?" 58 : 700-704, 2005

17 Reis-Filho JS, "Metaplastic breast carcinomas are basal-like tumours" 49 : 10-21, 2006

18 Weigelt B, "Metaplastic breast carcinomas are basal-like breast cancers:a genomic profiling analysis" 117 : 273-280, 2009

19 Downs-Kelly E, "Matrix-producing carcinoma of the breast:an aggressive subtype of metaplastic carcinoma" 33 : 534-541, 2009

20 Pramudji C, "In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter" 7 : 4272-4279, 2001

21 Osako T, "Histogenesis of metaplastic breast carcinoma and axillary nodal metastases" 59 : 116-120, 2009

22 SOrlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications" 98 : 10869-10874, 2001

23 Petrelli F, "Current data of targeted therapies for the treatment of triple-negative advanced breast cancer:empiricism or evidence-based?" 18 : 1467-1477, 2009

24 Baselga J, "Critical update and emerging trends in epidermal growth factor receptor targeting in cancer" 23 : 2445-2459, 2005

25 Yamaguchi R, "Clinicopathologic study of 53 metaplastic breast carcinomas:their elements and prognostic implications" 41 : 679-685, 2010

26 Pezzi CM, "Characteristics and treatment of metaplastic breast cancer:analysis of 892 cases from the National Cancer Data Base" 14 : 166-173, 2007

27 Savage K, "Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas:a morphologic,ultrastructural,immunohistochemical,and in situ hybridization analysis" 13 : 90-101, 2007

28 Lisanti MP, "Caveolae,caveolin and caveolin-rich membrane domains:a signalling hypothesis" 4 : 231-235, 1994

29 Sotiriou C, "Breast cancer classification and prognosis based on gene expression profiles from a population-based study" 100 : 10393-10398, 2003

30 Ferrara N, "Bevacizumab(Avastin),a humanized anti-VEGF monoclonal antibody for cancer therapy" 333 : 328-335, 2005